![Kristina Sjöblom Nygren](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 20 439 $ au 31/07/2026
Kristina Sjöblom Nygren is currently an Independent Director at Infant Bacterial Therapeutics AB since 2018.
Former positions include Chief Medical Officer at Egetis Therapeutics AB from 2021 to 2026, Chief Medical Officer, EVP & Head-Development at Santhera Pharmaceuticals Holding AG from 2017 to 2020, Vice President & Head-Clinical Development at Swedish Orphan Biovitrum AB, Group Director-Development at AstraZeneca AG from 2007 to 2008, and Medical Director at Pfizer AG from 1998 to 2003.
Education includes a doctorate from Karolinska Institutet.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2025 | 32 498 ( 0,01% ) | 20 439 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Directeur/Membre du Conseil | 15/05/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
| EGETIS THERAPEUTICS AB | Directeur Technique/Scientifique/R&D | 30/04/2026 |
| SANTHERA PHARMACEUTICALS HOLDING AG | Directeur Technique/Scientifique/R&D | 31/12/2020 |
Astrazeneca AG | Corporate Officer/Principal | 01/01/2008 |
Pfizer AG | Directeur Technique/Scientifique/R&D | 01/01/2003 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 7 |
|---|---|
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
Astrazeneca AG | |
Pfizer AG | |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Egetis Therapeutics AB
 Egetis Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Infant Bacterial Therapeutics AB
 Infant Bacterial Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of gastroschisis | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
